A T-cell therapy that targets a protein only expressed on HPV-positive cancers has shown low toxicity and impressive responses in some patients enrolled in a phase 1/2 clinical trial.
There is great interest in evaluating the link between hypercalcemia and prognosis in ccRCC by researching the genes that influence calcium levels.
Recent and upcoming case reports suggest possible cases of gluteal and other implant-associated ALCLs, raising questions about the cancer risk across all types of implants.
The problem of low representation of racial minorities is especially urgent during the era of immunotherapy trials.
A phase 0 study of ribociclib in patients with recurrent glioblastoma seeks to inform the feasibility of the use of CDK 4/6 inhibitors for deadly brain tumors.
A treatment delay of 6 months was found to result in up to a 67.3% loss in social value for patients receiving chimeric antigen receptor T-cell therapy.
Pexa-Vec, in combination with sorafenib, has failed an interim futility analysis, leading to the early termination of the trial.
The microbiome could have a role in the diagnosis of PrCa.
Radiation-enhancing particles appear to be a promising tool for improving results with radiotherapy — perhaps even across various cancers.
Recent advances in predictive biomarker development clarify how best to determine PD-L1 expression in tumor cells.
A team of researchers sought to determine if BWH Tumor Classification System classified tumors more accurately than AJCC 8, and their sensitivity and specificity for predicting poor outcomes.
Researches took a critical look at noninferiority trials and determined that when a new intervention is “not worse,” the possibility exists that it is not better, either.
Researchers showed that survival in pancreatic cancer may be influenced by the tumor microbiome and that tumor growth can be influenced via fecal transplantation.
Immune checkpoint inhibitor therapies have improved survival in patients with non-small cell lung cancer, but they have also been linked to immune-related adverse events affecting various organs, including the lungs.
The authors proved that the drug was able to cross the blood-brain barrier in a concentration that was effective.